Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.
Matsui
K
K
Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
Masuda
N
N
Fukuoka
M
M
Yana
T
T
Hirashima
T
T
Komiya
T
T
Kobayashi
M
M
Kawahara
M
M
Atagi
S
S
Ogawara
M
M
Negoro
S
S
Kudoh
S
S
Furuse
K
K
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male
D005047:Etoposide; D016190:Carboplatin